Gut inflammation in chronic fatigue syndrome by Lakhan, Shaheen E & Kirchgessner, Annette
REVIEW Open Access
Gut inflammation in chronic fatigue syndrome
Shaheen E Lakhan
*, Annette Kirchgessner
Abstract
Chronic fatigue syndrome (CFS) is a debilitating disease characterized by unexplained disabling fatigue and a com-
bination of accompanying symptoms the pathology of which is incompletely understood. Many CFS patients com-
plain of gut dysfunction. In fact, patients with CFS are more likely to report a previous diagnosis of irritable bowel
syndrome (IBS), a common functional disorder of the gut, and experience IBS-related symptoms. Recently, evidence
for interactions between the intestinal microbiota, mucosal barrier function, and the immune system have been
shown to play a role in the disorder’s pathogenesis.
Studies examining the microecology of the gastrointestinal (GI) tract have identified specific microorganisms whose
presence appears related to disease; in CFS, a role for altered intestinal microbiota in the pathogenesis of the dis-
ease has recently been suggested. Mucosal barrier dysfunction promoting bacterial translocation has also been
observed. Finally, an altered mucosal immune system has been associated with the disease. In this article, we dis-
cuss the interplay between these factors in CFS and how they could play a significant role in GI dysfunction by
modulating the activity of the enteric nervous system, the intrinsic innervation of the gut.
If an altered intestinal microbiota, mucosal barrier dysfunction, and aberrant intestinal immunity contribute to the
pathogenesis of CFS, therapeutic efforts to modify gut microbiota could be a means to modulate the development
and/or progression of this disorder. For example, the administration of probiotics could alter the gut microbiota,
improve mucosal barrier function, decrease pro-inflammatory cytokines, and have the potential to positively influ-
ence mood in patients where both emotional symptoms and inflammatory immune signals are elevated. Probiotics
also have the potential to improve gut motility, which is dysfunctional in many CFS patients.
Introduction
Chronic fatigue syndrome (CFS) is a clinical condition
characterized by persistent and unexplained relapsing
fatigue that is worsened by physical and mental exertion
[1,2]. According to the Centers for Disease Control
(CDC) report, the overall prevalence of CFS in the USA
is as many as 4 million people [3,4]. Up to 80% of those
affected are women [5]. These individuals suffer from
severe fatigue that impairs daily activity, diminishes
q u a l i t yo fl i f e( Q O L )f o ry e a r s ,a n dh a sn ok n o w nc u r e .
CFS represents an economic burden for society and
healthcare institutions [6].
The CDC originally proposed the term CFS in 1988.
In 1994, the International CFS Study Group published a
revised and more inclusive case definition which defines
CFS on the fulfillment of two major criteria: chronic
fatigue of at least 6 months duration, which is accompa-
nied by various rheumatologic, infectious and
neuropsychiatric symptoms [7]. Although considerable
progress has been made in recent years, a major gap in
the knowledge of the pathogenesis of CFS remains and
has precluded the discovery of effective forms of treat-
ment. Moreover, the diagnosis of CFS is highly proble-
matic since no biological markers specific to this disease
have been identified. Thus, CFS is a diagnosis of exclu-
sion [7].
Along with disabling fatigue, CFS is characterized by
neuropsychological disturbances such as headaches,
myalgia, arthralgia, and post-exertional malaise; cogni-
tive difficulties, with impaired memory and concentra-
tion; un-refreshing sleep; and mood changes, such as
depression and anxiety [8]. In addition, many CFS
patients complain of gastrointestinal (GI) disturbances,
including abdominal pain or discomfort and an altera-
tion in bowel habit. In fact, patients with CFS are more
likely to report a previous diagnosis of irritable bowel
syndrome (IBS), a common functional disorder of the
gastrointestinal tract, and experience IBS-related symp-
toms [9]. Although the precise pathophysiology of CFS * Correspondence: slakhan@gnif.org
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morbidities in CFS suggests that the underlying patho-
physiological mechanisms cannot be confined to an
organ (e.g., the brain), but rather must involve an inte-
grating system or mechanism such as the brain-gut axis
and the autonomic nervous system.
There is a growing body of literature describing
immune dysfunction in CFS [10]. A possible involve-
ment of the immune system is supported by the obser-
vation that the onset of CFS is often preceded by virus
infections and a “flu-like” illness. For example, infectious
mononucleosis has been shown to be a risk factor for
developing CFS [11]. Immune activation is also sug-
gested by an elevation of pro-inflammatory cytokines, an
increased expression of T lymphocyte activation mar-
kers, such as CD26 and CD38 [12] and decreased func-
tion of natural killer (NK) cells (for review see [13]).
Both physical and psychological stressors have been
found to activate the hypothalamic-pituitary-adrenal
(HPA) axis, an important link between the brain and
the immune system [14]. Corticotrophin-releasing hor-
mone (CRH) produced in the hypothalamus, is the pri-
mary hypothalamic regulatory peptide of the HPA axis
and its release has been shown to be controlled by cir-
culating pro-inflammatory cytokines, especially interleu-
kin (IL)-6 [15]. Thus, the increase in pro-inflammatory
cytokines seen in CFS patients may be involved in an
exaggerated activation of the HPA axis [14].
The frequent association between CFS and IBS could
also be governed by elevated circulating pro-inflamma-
tory cytokines acting either locally or on the brain-gut
axis. Patients with IBS were shown to have increased
plasma levels of IL-6 and IL-8 [16]. Moreover, patients
with both IBS and CFS were found to have, in addition,
increased levels of two other pro-inflammatory cytokines,
IL-1b and tumor necrosis factor (TNF)-a [16]. Given
that other studies have shown a variety of findings (mast
cell activation, increased lymphocytes) suggesting a state
of low-grade inflammation or immune activation in the
mucosa and lamina propria of the bowel [17], increased
serum concentrations of cytokines have been interpreted
as evidence of spill-over from a primary focus in the gut.
Thus, pro-inflammatory cytokines may be involved in the
exaggerated activation of the HPA axis and thereby pro-
mote a coordinated central response to stress, such as GI
inflammation and dysfunction.
There is now evidence that CFS is associated with
marked alterations in the gut microbiota, with lower
levels of Bifidobacteria and higher levels of aerobic bac-
teria [18]. Gut pathogens can communicate with the
CNS and influence emotional behaviors such as anxiety
and depression, even at extremely low levels and in the
a b s e n c eo fa ni m m u n er e s p o n s e[ 1 9 , 2 0 ] .I na d d i t i o n ,
probiotics or live microorganisms which confer a health
benefit on the host, have the potential to decrease
mood-regulating systemic pro-inflammatory cytokines,
decrease oxidative stress and improve nutritional status
when orally consumed (see below; [18]). Probiotic lactic
acid producing-bacteria have been shown to prevent
and alleviate GI disturbances and to normalize the cyto-
kine profile which might be of an advantage for patients
suffering from CFS [21].
I nt h ec a s eo fC F S ,e v i d e n c ef o ras y n e r g i s mb e t w e e n
aberrant gut microbiota, mucosal barrier dysfunction,
and altered mucosal immunity contributing to the disor-
der’s pathogenesis has begun to evolve. Research shows
that patients with CFS have alterations in gut microbiota
[22]. Moreover, emerging studies have demonstrated
that pathogenic and non-pathogenic gut microbiota may
influence mood-related symptoms and even behavior in
animals and humans. These findings lend further sup-
port to the presence of a gut-brain interface, one that
may be modulated by gut microbiota.
Experimental data also show that inflammation, even
if mild, can lead to persistent changes in GI nerve and
smooth muscle function, resulting in dysmotility, hyper-
sensitivity, and dysfunction. Furthermore, alterations in
gut function are observed after the resolution of an
acute intestinal inflammation [23,24]. The enteric ner-
vous system (ENS), the intrinsic innervation of the
bowel, controls virtually all GI functions (e.g., motility,
secretion, blood flow, mucosal growth and aspects of
the local immune system). Whether the persistent
alterations in gut function observed in the majority of
CFS patients are due to inflammation-related changes in
the properties of enteric nerves is unknown.
This review will provide a brief overview of the cur-
rent understanding of the role of gut inflammation in
CFS. Despite advances in the understanding of the
pathophysiology of CFS, therapeutic options for combat-
ing the symptoms of CFS are still not available.
Viral infection
Early conceptualizations of CFS focused on the role of
viral infection. This is not surprising since in 60 to 80%
of published reports, CFS presents with acute onset of
illness, with systemic symptoms similar to influenza
infection that do not subside. Numerous researchers
have tried to correlate infection by several microorgan-
isms with the onset of CFS. For example, the human
parvovirus (HPV)-B19 has been the most reported CFS-
associated virus [25]. Although several studies have
detected parvovirus B19 DNA in the GI tract of CFS
patients, it is not consistently detected in all patients
[25]. Another difficulty is associating the onset of CFS
with the presence of antibodies to HPV-B19.
Other studies have suggested that infection by another
virus, the human herpes virus-6 (HHV-6), a neurotropic,
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in patients with CFS than in healthy controls [26]. How-
ever, using real-time PCR, high loads of HHV-6 DNA
were detected in most CFS and control biopsies [27].
Other studies attempted to show an association between
Epstein-Barr virus (EBV) infection and postinfectious
onset of CFS. EBV infection has been shown to cause
extreme fatigue during the acute illness and to be a risk
factor for developing CFS, with a prevalence rate of 8%
observed at 6 months [11,28]. However, EBV was found
in 15-30% of all biopsies [25]. Thus, the involvement of
EBV in addition to various enteroviruses, and the
human T-lymphotropic virus type 2 (HTLV-2) has not
been conclusively proven [29].
In October 2009, Lomardi et al. reported finding a
gammaretrovirus in peripheral blood mononuclear cell
(PBMC) DNA from about 67% of CFS patients com-
pared to only 3.6% of healthy persons using PCR testing
[30]. The agent was named xenotropic MLV-related
virus (XMRV) because its env gene was nearly identical
to that of xenotropic MLV, an infectious endogenous
MLV that preferentially infects cells from foreign spe-
cies, including humans. Almost half of the CFS patients
in this study described the onset of their symptoms as
related to an acute viral disease. In addition, virus isola-
tion and antibody detection were reported in some CFS
patients.
Confirmation of an association and etiologic role of
XMRV in CFS is important because it could provide a
useful diagnostic test and might lead to new treatment
interventions. Inhibitors of XMRV such as the integrase
inhibitor raltegravir, are now available. However, two
recent studies from the United Kingdom using PCR
testing alone or together with serologic testing reported
negative XMRV results in CFS patients [31,32]. XMRV
was also not found by PCR testing in CFS patients from
the Netherlands [33], China [34], or the United States
[35], questioning the association of XMRV with CFS.
Endotoxemia
Although confidence in the link between infection and
CFS pathogenesis has waned [8], recent studies have
suggested that infection with gut pathogens could be
related to CFS onset.
Raised serum concentrations of IgA and IgM to lipo-
polysaccharide (LPS) of gram-negative enterobacteria,
such as Pseudomonas aeruginosa, Morganella morganii,
Proteus mirabilis, Pseduomonas putida, Citrobacter
koseri, and Klebsiella pneumoniae have been reported in
CFS patients [12]. The prevalence and median values for
serum IgA against the LPS of enterobacteria were signif-
icantly greater in patients with CFS than in normal
volunteers and patients with partial CFS. Moreover,
serum IgA levels were significantly correlated to the
severity of illness, as measured by the FibroFatigue scale
[12]. The FibroFatigue scale is an observer’sr a t i n gs c a l e
with 12 items measuring pain, muscular tension, fatigue,
concentration difficulties, failing memory, irritability,
sadness, sleep disturbances, and autonomic disturbances
and irritable bowel, headache, and subjective experience
of infection [36]. It is a reliable and valid measuring
instrument that is used to monitor symptom severity
and change during treatment of CFS patients [36].
Normally, the intestinal epithelium acts as a continu-
ous barrier to avoid LPS translocation; however, some
endogenous or exogenous events may alter this protec-
tive function [37]. This may induce an increased bacter-
ial translocation and thus increased serum endotoxin
concentrations which, in turn may trigger an immune
response [38]. Thus, the increased serum IgA and IgM
levels against LPS in CFS indicate the presence of
increased gut permeability and an immune response
mounted against LPS of the enterobacteria [12].
Gut microbiota
The human GI tract contains a complex and delicately
balanced ecosystem of more than 17 bacterial families
encompassing 400 to 500 different microbial species.
The main genera of these commensal bacteria are: Lac-
tobacillus, Bifidobacteria, Bacteroides, Clostridia, Fuso-
bacteria, Eubacteria, Peptococcus, Streptococcus,
Escherichia and Veillonella. They regulate a myriad of
host processes and provide several nutrients to their
host and their symbionts within the microbial commu-
nity. In healthy individuals, these relationships are
thought to occur in equilibrium; however, the normal
balance of gut microbiota can be altered by a number of
factors and this is turn can contribute to certain func-
tional disorders [39]. For example, the number of differ-
ent commensal bacteria is altered in inflammatory
bowel disease (IBD). IBD patients have increased bacter-
oides, adherent or invasive Escherichia coli, and entero-
cocci, and reduced Bifidobacteria and Lactobacillus
species [40].
The composition of the gut microbiota can be altered
by various factors including stress. Psychological stress
alters the gut microbiota towards decreased numbers of
Bifidobacteria and Lactobacilli [41]. Bifidobacteria are a
group of bacteria that have been shown to reduce intest-
inal LPS levels and LPS-induced activation of nuclear
factor-kappa B (NF-B) in mice [42]. Inhibition of LPS-
induced NF-B activation was accompanied by a dose-
dependent decrease of pro-inflammatory cytokines and
cyclooxygenase 2 [42]. Stress in neonatal Rhesus mon-
keys was reported to suppress the numbers of Lactoba-
cilli in the fecal flora in association with increased
susceptibility for opportunistic infections [43]. Restraint
conditions, acoustic stress and food deprivation have all
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animal studies [44,45]. Interestingly, stress (e.g., psycho-
logical, physical exhaustion) is a well-established trigger
factor for CFS [12].
Investigations have documented that there are marked
alterations in the gut microbiota of CFS patients, with
lower levels of Bifidobacteria and higher levels of aero-
bic bacteria [18]. Dr. Henry Butt and colleagues from
the University of Newcastle, Australia have been exam-
ining the intestinal microbiota of CFS patients for a
number of years. In 1998, they presented the first evi-
dence of altered fecal microbiota in CFS patients com-
pared to normal, healthy controls [46]. The mean
distribution of the Gram negative Escherichia coli as a
percentage of the total aerobic flora of control subjects
was 92.3% compared to 49% in CFS patients. Among
aerobes, the D-lactic acid producing Enterococcus and
Streptococcus species were strongly over-represented in
CFS patients. These findings were recently confirmed
[22]. Among anaerobic bacteria, Prevotella was the most
commonly overgrown bacteria. Moreover, it was shown
that the higher the aerobic enterococcal count, the more
severe the neurological and cognitive deficits including
nervousness, memory loss, forgetfulness and confusion
[46]. Consequently, high plasma LPS levels in CFS could
result from an increased production of endotoxin upon
changes in the gut microbiota [47].
Mucosal barrier function
To protect itself from uncontrolled inflammatory
responses, the intestinal epithelium has developed
mechanisms to restrain bacterial growth, limit direct
contact with the bacteria, and prevent bacterial dissemi-
nation into underlying tissue. The mucosal barrier,
which consists of only a single layer of epithelial cells, is
one of the most important components of the innate
immune system, and all that separates the inside of the
body from a very “dirty” outside environment. Thus,
mucosal barrier function is a key component in the
arsenal of defense mechanisms required to prevent
infection and inflammation. Mucosal barrier function is
maintained by several interrelated systems, including
mucous secretion, chloride and water secretion, and
binding together of epithelial cells at their apical junc-
tions by tight junction proteins. Together, they act as
the “gatekeeper” of the mucosal barrier.
Disruption of mucosal barrier function occurs in CFS
as demonstrated by the increased serum concentrations
of IgA and IgM to LPS of gram-negative enterobacteria
[12]. Psychological stress disrupts the mucosal barrier
allowing increased entry of antigens and microorganisms,
which in turn is expected to stimulate hyperactive
responses in the mucosal immune system. For example,
chronic water avoidance stress in rats induces increases
in the adherence of bacteria to intestinal epithelial cells,
bacterial internalization into enterocytes and the appear-
ance of bacteria in the lamina propria [48]. Consequently,
mucosal barrier dysfunction causes alterations in gut
motility, abnormal secretion, and changes in visceral sen-
sation that could contribute to symptom generation. This
may at least partially explain the link between stress and
CFS. The relationship between IBS and CFS may also
reflect in part disorders in gut permeability as altered gut
microbiota (e.g., higher numbers of Veillonella and Lac-
tobacillus than healthy controls) and a disrupted mucosal
barrier are found in patients with IBS [49,50]. Further-
more, IBS patients with high acetic acid or propionic acid
levels presented more severe symptoms, impaired quality
of life and negative emotions [50].
Butt and colleagues reported that fatigue presentation
i nC F Sp a t i e n t sw i t hs y m p t o m so fI B Sw a sm o r es e v e r e
than in CFS patients without irritable bowel [46].
Furthermore, patients with both CFS and IBS had
poorer appetite, increased abdominal pain, increased
severity of loose stools, diarrhea, nausea, and gastric
reflux. The gut microbiota influences the sensory, motor
and immune system of the gut and interacts with higher
brain centers even at extremely low levels [50]. So aber-
rant gut microbiota and gut barrier dysfunction may
actually be creating an “irritable” bowel. Altered intest-
inal microbiota and gut barrier dysfunction could also
contribute to the symptoms of CFS through increased
translocation of LPS from gram-negative enterobacteria.
Therapeutic restoration of mucosal barrier
function
Since altered intestinal microbiota and gut barrier dys-
function barrier are found in CFS [18], they offer poten-
tial targets for intervention that would include
modulation of the gut microbiota to correct an imbal-
ance, as well as tightening of interepithelial junctions.
Enhancement of barrier function by probiotic bacteria
has been observed in both in vitro models and in vivo
animal models [51].
Probiotics are live microorganisms with a vast array of
therapeutic potential for GI disease. They have a benefi-
cial effect on the intestinal mucosa via several proposed
mechanisms that include inhibition of the mucosal adhe-
sion of pathogens, improvement of the barrier function
of the epithelium, and alteration of the immune activity
of the host. They may also regulate intraluminal fermen-
tation and stabilize the gut microbiota [39]. In addition,
probiotics have recently emerged as promising adjunctive
therapy in treating IBS, with B. infantis becoming the
frontrunner for treatment (for review see [52]).
Probiotic bacteria are Lactobacilli spp., certain types of
Streptococcus,a n dBifidobacteria spp., but also other
non-pathogenic bacilli such as E. coli-Nisle 1917 and
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short chain fatty acids, an action that results in
decreased luminal pH and production of bactericidal
proteins. Butyric acid, a byproduct of bacterial fermenta-
tion of fiber, has been shown to nourish colonic entero-
cytes, enhancing mucosal integrity [53]. In addition,
probiotics may improve bowel dysmotility [53].
Researchers have demonstrated the utility of probio-
tics for mood regulation in CFS patients [54]. Adminis-
tration of Lactobacillus casei strain Shirota (LcS;
24 billion cfu/day) to adult patients meeting the formal
diagnostic criteria for CFS, was found at eight weeks to
cause a significant rise in both Lactobacillus and Bifido-
bacteria in those taking the LcS and there was also a
significant decrease in anxiety symptoms [54]. The ele-
vation of Bifidobacteria levels should be considered a
positive finding, particularly when considering that Bifi-
dobacteria levels may be low in CFS [18].
Bifidobacteria appear to play an important role in
maintaining the gut barrier. An increase in Bifidobac-
teria in ob/ob mice was associated with a significant
improvement of gut permeability measured in vivo;t h i s
improvement was linked to an increase in tight junction
mRNA expression and protein distribution [47]. In addi-
tion, the rise in Bifidobacteria was correlated with a
decrease in plasma LPS concentrations; therefore, a sig-
nificant reduction in markers of oxidative and inflamma-
tory stress [47].
Bifidobacterium infantis can boost serotonin levels in
areas of the brain associated with anxiety and depres-
sion. Improvements in anxiety scores among those CFS
patients consuming LcS bacteria are especially note-
worthy [54]. The idea that implanting the gut with Lac-
tobacillus strains may improve quality of life and mental
health is not a new one. Dr. George Porter Phillips first
reported in 1910 that although Lactobacillus tablets and
powder were ineffective, a gelatin-whey formula with
live lactic acid-producing bacteria improved depressive
symptoms in adults with melancholia [55]. Overall, pro-
biotics will likely have an emerging therapeutic role in
treating CFS.
Cytokines and inflammation
CFS is typically characterized by a chronic, low-grade
inflammation. Although fatigue severity appears to cor-
relate with inflammatory disease activity and is therefore
consistent with an immunological model of CFS [12], it
is not known whether inflammation causes fatigue.
Results from a population-based study indicate that peo-
ple with CFS had increased markers of peripheral
inflammation when compared to healthy controls, but
had a similar inflammatory profile when compared to
unhealthy subjects who did not meet the criteria for
CFS [56].
It is unlikely that CFS “causes” increased inflamma-
tion. Rather people with fatiguing conditions are likely
to exhibit “unwellness” symptoms for a variety of rea-
sons. One such reason may be an increase in peripheral
pro-inflammatory signaling based on overwhelming evi-
dence that pro-inflammatory cytokines are capable of
inducing all the cardinal symptoms of CFS in humans
[57,58]. Thus, factors that increase inflammation, such
as stress and depression can increase peripheral inflam-
mation, significantly increasing the risk in individuals
with CFS of subsequently developing vascular disease,
metabolic disease and dementia.
Several groups have reported evidence of chronic
immune dysfunction in CFS although the exact nature
of this dysfunction remains unclear. While initial studies
generally suggested immunosuppression [59], recent
years have seen increased interest in the possibility that
activation of the innate immune response might contri-
bute to symptom development in CFS [59,60]. Studies
have reported increased plasma concentration of the
acute phase reactant c-reactive protein (CRP) in patients
with CFS. Other findings include higher frequencies of
various autoantibodies. A significant increase in the
numbers of B cells with CD20+ CD5+ phenotype which
is correlated with autoantibody production and with
CD21 markers that is a ligand for retroviruses was also
found in patients with CFS [61].
CFS has a propensity to over-produce pro-inflammatory
cytokines (e.g., TNF-a coupled with a decreased production
of anti-inflammatory cytokines. A principal avenue of inves-
tigation has been the measurement in blood of immune
signals conducted by cytokines. In animal studies, adminis-
tration of pro-inflammatory cytokines (IL-1, TNF-a,a n d
IL-6) directly into the brain can induce “sickness behaviors”
that strongly resemble the symptoms of CFS. In particular,
decreased motor activity, altered food and water intake,
sleep and cognition have been linked to increases in the
levels of IL-1b, IL-6 and TNF-a [57]. Furthermore, in
humans, systemically administered pro-inflammatory cyto-
kines, such as IL-6 and TNF-a typically induce a systemic
inflammatory response where one of the major symptoms
is intense fatigue.
The sensation of fatigue or exhaustion is prevalent in
a number of infectious and chronic inflammatory dis-
ease states including IBD, systemic lupus erythematosus
and ankylosing spondylitis [62]. In rheumatoid arthritis
and IBD, in which TNF-a plays an integral role, fatigue
is markedly improved by treatment with anti-TNF-a
agents. Thus, amelioration of fatigue is mediated
through an anti-inflammatory effect showing that the
CNS is extremely susceptible to immunological reac-
tions that occur during disease and injury.
The TNF-a inhibitors are a group of drugs that may
provide benefit in CFS. One TNF-a inhibitor,
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the treatment of six patients with CFS in a pilot study
[63]. Unfortunately, this trial was not published as a
paper but only as a meeting abstract. The use of TNF-a
inhibitors in CFS is strongly supported by data on the
immune responses in CFS, and data from gene expres-
sion studies [64,65]. Thus, it is important to repeat this
work and carry out a larger clinical trial of etanercept in
patients with CFS.
On the basis of the results of gene expression studies,
ac l i n i c a lt r i a lo fI F N - b was proposed in CFS patients.
IFN-b is associated with the regulation of humoral
immune responses and immune responses against viral
infections. IFN-b stimulates the activity of NK cells,
which are considered to be inefficient in patients with
CFS. It selectively inhibits the expression of some mito-
chondrial genes that are implicated by gene studies in
patients with CFS [65]. Finally, IFN-b is a licensed treat-
ment for multiple sclerosis, helping in reduction of fati-
gue. The pathogenesis of multiple sclerosis is also
thought to be cytokine mediated, as has been shown in
CFS [65].
Broderick et al. recently demonstrated that CFS is
associated with a profound imbalance in the regulation
of immune function [66]. In this study, instead of ana-
lyzing immunological markers individually, network ana-
lysis was applied to study the co-expression of 16
cytokines in CFS subjects and healthy controls. Analysis
showed consistent and significantly attenuated patterns
of Th1 and Th17 immune responses in CFS in the con-
text of a well-established Th2 inflammatory milieu.
These patterns would have escaped detection had the
analysis focused solely on differential expression of indi-
vidual cytokines.
Interestingly, the cytokine co-expression patterns
described in this study, were consistent with the disrup-
tive effects of latent viral infection by pathogens such as
EBV. Viral triggers such as EBV have long been sus-
pected of involvement in the onset and persistence of
CFS. However, this virus is not consistently detected in
all patients [25]. While other causes may underlie the
cytokine expression pattern observed in CFS patients
many of these are at least consistent with some of the
disruptive effects of chronic viral infection.
Effects of inflammation on the gut
Patients with CFS manifest symptoms suggestive of dis-
turbed gut function, such as abdominal pain, diarrhea
and/or constipation [9]. Under both physiological and
pathological conditions, the ENS, the intrinsic innerva-
tion of the bowel, regulates intestinal mucosal function
and coordinates the activity of the GI tract. The ENS is
a component of the autonomic nervous system with the
unique ability to function independently from the CNS
(for review, see [67]). Enteric ganglia are organized into
two major ganglionated plexuses, namely the myenteric
(Auerbach’s) and submucosal (Meissner’s) plexus, and
contain a variety of functionally distinct neurons, includ-
ing primary afferent neurons, interneurons, and motor
neurons, synaptically linked to each other in
microcircuits.
While the myenteric plexus mainly regulates intestinal
motility, the submucosal plexus together with nerve
fibers in the lamina propria are involved in regulating
epithelial transport. These nerves form networks within
the lamina propria of both crypts and villi with the
terminal axons in close contact with the basal lamina,
an ideal position not only to affect epithelial cell func-
tions but also to detect absorbed nutrients and antigens.
These substances or released mediators from epithelial
cells may act on the nerve terminals to change the prop-
erties of enteric neurons and cause peripheral sensitiza-
tion. Consequently, permanent or even transient
structural alterations in the ENS disrupt normal GI
function. Since the ENS controls the motility and secre-
tion of the bowel these abnormalities indicate the
impact of inflammation on neural signaling in the ENS.
Several studies have demonstrated ENS structural
changes associated with gut inflammation. For example,
damage to axons has been observed in the inflamed
human intestine in episodes of IBD [68-70]. Other
changes that occur in the ENS during inflammation
include altered neurotransmitter synthesis, content, and
release, changes in glial cell numbers and a myenteric
ganglionitis associated with infiltrates of lymphocytes,
plasma cells and mast cells [71,72]. In fact, conse-
quences of intestinal inflammation, even if mild, persist
for weeks beyond the point at which detectable inflam-
mation has subsided (for review see [73]). Thus, persis-
tent changes in GI nerve function, resulting in
dysmotility, pain, and gut dysfunction long after the
resolution of the initiating inflammatory event could
contribute to GI disorders observed in CFS.
Oxidative stress
It is well known that CFS is accompanied by increased
oxidative stress. People with chronic conditions, such as
CFS have lower levels of L-glutathione [74]. Research
has shown that L-glutathione levels in cells can be dra-
matically depleted by excessive oxidative stress. In turn,
L-glutathione deficiency has been shown to contribute
to oxidative stress and disease, resulting in a vicious
cycle.
Oxidative stress arises when there is a marked imbal-
ance between the production of reactive oxygen species
(ROS) and their removal by antioxidants. In reaction to
mild oxidative stress, tissues often respond by producing
more antioxidants; however, severe persistent oxidative
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its ability to produce more antioxidants, leading to
lower antioxidant levels and as well as injury in the
tissues.
8-OH-deoxy guanosine (8-OHdG) is a commonly used
and highly sensitive marker of total oxidative stress in
the body. Upon DNA repair, 8-OHdG is excreted in the
urine. Numerous studies have indicated that urinary
8-OHdG is not only a biomarker of generalized cellular
oxidative stress, but also a risk factor for many diseases
including CFS. Elevated urinary 8-OHdG DNA was
detected in patients with CFS. Moreover, the level of
urinary 8-OHdG in CFS correlated with the severity of
depression and malaise [75]. Thus, increased activation
of oxidative and nitrosative (IO and NS) pathways, plays
a role in CFS. Moreover, measuring urinary 8-OHdG
m a yb eac o n v e n i e n tm e t h o dfor evaluating oxidative
DNA damage in patients with CFS and could be a sensi-
tive biomarker helpful for the early diagnosis of patients
with CFS.
Maes proposed that IO and NS pathways play a key
role in the pathophysiology of CFS [76]. Increased
plasma concentrations of pro-inflammatory cytokines,
oxidative damage, increased COX-2 production, and
increased translocation by gram-negative enterobacteria
can generate CFS-like symptoms including fatigue, a flu-
like malaise, pain, symptoms of IBS, and neurocognitive
disorders. In addition, aberrations in IO and NS path-
ways are interrelated.
For example, viral and bacterial infections and gut-
derived inflammation may induce NF-Ba n dc o n s e -
quently COX-2, inducible nitric oxide synthase (iNOS)
and increased levels of pro-inflammatory cytokines.
These inflammatory pathways and persistent or reacti-
vating infections induce ROS and radical nitrogen spe-
cies (RNS), which in turn may damage membrane fatty
acids, proteins, DNA and mitochondria. As a conse-
quence, some cellular immune functions may be sup-
pressed, for example, lowered NK cell activity and
ex vivo expression of T cell activation markers, such as
CD69. Depletion of antioxidants in patients with CFS,
partially due to inflammation, may further impair the
protection again ROS and RNS, causing more damage
to fatty acids, proteins, DNA and mitochondria [76].
Hydrogen sulfide
Alterations of the gut microbiota may have serious con-
sequences for the host health. Overgrown pathogenic
bacteria found in the oral cavity and GI tract produce
the “toxic gas” hydrogen sulfide (H2S) when they come
in contact with heavy metals. H2S, a colorless, flam-
mable and water-soluble gas with the characteristic odor
of rotten eggs, has been known for decades because of
its toxicity and as an environmental hazard [77].
Inhibition of mitochondrial respiration, more potent
than that of cyanide, resulting from blockade of
cytochrome c oxidase is the main mechanism of H2S
toxicity [78].
H2S is normally found in the body, which suggests
that this molecule could have physiologic relevance. The
mucosa of the gut is continuously exposed to H2Sg e n -
erated by sulfate-reducing bacteria [79]. However, too
much H2S, produced by the overgrowth of harmful,
pathogenic bacteria as occurs during inflammation
causes the intestinal epithelial barrier to break down.
Increased levels of bacterial H2S stimulate the produc-
tion of destructive compounds called ROS, which inhibit
mitochondrial function directly. An increase in ROS
caused by an imbalance between antioxidant defenses
and ROS production results in tissue damage and, even-
tually, cell death. This is a key mechanism for the devel-
opment of gut infections. Thus, there is evidence that
H2S is involved in chronic (long-term) inflammation of
the gut [80].
People with CFS were shown to have higher concen-
trations of intestinal bacteria than normal, which prob-
ably leads to higher levels of H2S. Professor Kenny De
Meirleir of the Brussels Free University and his team say
high levels of H2S caused by an intestinal overgrowth of
Gram positive D/L lactate-producing bacteria play a
major role in CFS and lead to a series of reactions in
your body that leave cells devoid of oxygen and energy.
Understanding the role of the intestinal barrier and its
breakdown is an area of research that is currently
receiving a great deal of attention as is considered by
many scientists as the real basis for CFS [12]. Interest-
ingly, it has recently been shown that H2Si sa l s op r e -
sent in gut nerves in humans and guinea pigs.
Schemann and colleagues found that more than 90% of
neurons in the ENS contain enzymes that produce H2S
[81]. In addition, H2S increased neuronal electrical activ-
ity and significantly increased mucosal secretion. These
finding suggest H2S is a novel gut-signaling molecule
and may be the third gaseous transmitter in addition to
nitric oxide and carbon monoxide.
Mitochondrial failure and CFS
Dr. Sarah Myhill and colleagues have proposed that CFS
is linked to “mitochondria failure” [82]. Mitochondria
use fuel molecules derived from food to produce energy
by oxidative metabolism in the form of adenosine tri-
phosphate or ATP, which when hydrolysed to the dis-
phosphate, ADP, releases energy to produce muscle
contractions, nerve impulses and all the energy-consum-
ing processes needed to synthesize all of the complex
molecules of the body. ATP recycles approximately
every 10 seconds in a healthy individual. However, when
mitochondria are impaired the energy they supply will
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in CFS. Also, when a cell is filled with defective mito-
chondria, it not only becomes deprived of energy (ATP).
It can accumulate a backlog of unused fuel molecules
(glucose) and oxygen with disastrous effects. If the body
is short of ATP, it can make a very small amount
directly from glucose by converting it into lactic acid.
This is exactly what many individuals with CFS do.
They readily switch into anaerobic metabolism [83].
However, this results in serious problems.
The buildup of lactic acid in the blood, called lactic
acidosis is associated with muscle pain, heaviness, ach-
ing and soreness ("lactic acid burn”), and might actually
damage muscle and nerve tissue. People suffering from
CFS have difficulty increasing their fitness [84]. Their
response to incremental exercise is increased oxidative
stress with marked alterations of muscle membrane
excitability. Thus, mitochondrial dysfunction results in
fatigue and could produce symptoms of CFS.
There is considerable evidence that mitochondrial dys-
function is present in some CFS patients. Muscle biopsies
have shown abnormal mitochondrial degeneration in CFS
patients [82]. Mitochondrial dysfunction occurs in neu-
trophils in CFS patients [82]. Neutrophils are the major
effector cells of the immune system and the observed
mitochondrial dysfunction is bound to have a deleterious
effect on this system. Moreover, the degree of dysfunc-
tion was strongly correlated with the severity of their ill-
ness suggesting that the severity of a person’s CFS relates
to the severity of the mitochondrial dysfunction [82].
Coenzyme Q10
Deficiency of coenzyme Q10 (CoQ10) has been found in
some CFS patients [85]. CoQ10 is a mitochondrial
nutrient, which acts as an essential cofactor for the pro-
duction of ATP and displays significant antioxidant
activities and anti-inflammatory effects.
In a study conducted by Maes and colleagues, more
than 40% of patients with CFS had values below the
lowest CoQ10 value detected in normal, healthy controls
(490 microg/L). Moreover, CFS patients with very low
plasma CoQ10 (< 390 microg/L) suffered significantly
more from concentration and memory disturbances
[85]. Deficiency of CoQ10 is also found in fibromyalgia,
depression and a risk factor for atherosclerosis [86]. The
presence of CoQ10 deficiency may also explain the
accompanying depression seen in CFS and increased
morbidity due to chronic heart failure in CFS patients.
These results suggest that people with CFS might bene-
fit from CoQ10 supplementation in order to normalize
the low CoQ10 syndrome.
CoQ10 supplementation also appears to have a benefi-
cial effect on gut dysfunction observed in animal models
of colitis [87]. Over 12 weeks, the mice experienced a
recovery in loose stools and bleeding in the GI tract.
Since CoQ10 acts as an antioxidant, it may help lessen
the inflammation by reducing tissue damage caused by
gut pathogens. Future studies are required to determine
whether oral CoQ10 is beneficial in the prevention and/
or treatment of symptoms associated with CFS.
Conclusion
Clearly, much work remains in terms of understanding
the role of gut inflammation in CFS development.
Despite several studies showing health benefits of pro-
biotics, the enthusiasm for their application as well as
other means to alter the intestinal microbial ecosystem
in the prevention of CFS needs to be tempered due to
the current lack of knowledge of the normal gut micro-
biota, in addition to questions as to how it affects the
immune system. Future studies using newly developed
techniques to evaluate the gut microbiota in CFS
patients and/or animal models of CFS are certainly
needed. In addition, research on the effects of mucosal
barrier dysfunction on enteric nerves and their activity
in CFS are clearly warranted.
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